As you are aware the EU Clinical Trials Directive has become part of the UK's regulatory and legal landscape from 1 May, 2004. Richmond Pharmacology has welcomed the directive which will help to harmonise trial standards across the board.We support the MHRA (Medicines and Healthcare products Regulatory Agency) which regulates implementation of the Directive, and we applaud our industry partners who have ensured that the implementation does not slow down or hinder the competitiveness of the UK's clinical research industry.This guide has been put together following numerous client requests for more information and greater clarity on how the directive will impact on research projects, timelines and approval systems.Direction on the Directive

Latest news

Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director

August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read more

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Events

JSCPT 2025

5th –6th December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event